An interventional study of Ultrafiltration in Fluid Accumulation, Blood Pressure Management and End Stage Renal Disease (ESRD), sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University of Washington · Not applicable, Interventional, and Treatment
Among 18 studies in Kidney Failure, Chronic by University of Washington — 1 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · University of Washington.
Among the 18 studies in Kidney Failure, Chronic by University of Washington, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 18th registered.
2,108 studies on the registry are indexed under Kidney Failure, Chronic; 273 are open to participants now.
Browse Kidney Failure, Chronic studies →1 of the 18 studies in Kidney Failure, Chronic by University of Washington is open now, in 1 country.
By country, each count listing its studies:
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 120 is above the median of 57 across 1,569 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 120 across the 15 interventional studies, 58 across the 3 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Washington is the lead sponsor of 1,433 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.
1 of the studies in Kidney Failure, Chronic by University of Washington that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06288451University of WashingtonDePTH: De-emphasize PTH | 2027-02-28 |
Among the 18 studies in Kidney Failure, Chronic by University of Washington, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations.
This trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.
This is a randomized trial of patients who are receiving in-center hemodialysis treatments for end stage kidney disease and have clinical suspicion of fluid overload. Enrolled participants will be randomly assigned in 1:1:1 fashion to either a four-week ultrafiltration strategy, an eight-week ultrafiltration strategy, or continuation of their regular thrice weekly hemodialysis treatments. Each ultrafiltration strategy will add two extra four-hour ultrafiltration treatments per week plus pharmacist-guided tapering of blood pressure medications. We will test the impact of these strategies on primary outcomes of
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either:
Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered.
OR
Exclusion Criteria:
Two ultrafiltration treatments per week for up to 4 weeks; pharmacist guided tapering of blood pressure medications for up to 4 weeks; and regular thrice weekly hemodialysis treatments.
Procedure: Ultrafiltration
Two ultrafiltration treatments per week for up to 8 weeks; pharmacist guided tapering of blood pressure medications for up to 8 weeks; and regular thrice weekly hemodialysis treatments.
Procedure: Ultrafiltration
Regular thrice weekly hemodialysis treatments.
Ultrafiltration for 4 or 8 weeks compared to no ultrafiltration.
24-hour continuous ambulatory blood pressure
Blood pressure measured continously for a 24-hour period by wearing a blood pressure cuff on the upper arm.
Time frame: Measurement performed at baseline compared to measurement performed at 24 weeks.
Symptoms of congestion.
Change in sypmtoms of congestion caused by fluid overload which we will access by using the Kidney-modified Kansas City Cardiomyopathy Questionnaire.
Time frame: Questionnaire taken at Baseline compared the the questionnaire taken at 24 weeks.
Plan to share: Yes — All data and samples will be stored indefinitely for possible future uses. There will be no direct or indirect identifiers stored with the resources after this study is finished. Resources will be coded with study codes. We plan post de-identified data in public databases such as Dryad at study conclusion. NIH data sharing policies typically require us to post coded, deidentified individual-level data on one of the preferred platforms. We will work with our NIH project officer to post data after the study is finished to an appropriate platform. We may collaborate with colleagues and other researchers who demonstrate a legitimate research need for which data and samples from this study would be valuable. Future uses do not have any restrictions.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: We will share the study protocol, informed consent form, and statistical analysis plan at the beginning of the study and indefinitely. We will share the analytic code when it becomes available.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Feb 2030, 41 months after the start.
Of 347 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 41 months is above that.
Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 8 and three quarters within 46.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.